Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HB0017 (Betinukibart) in Healthy Volunteers
NCT04505033Phase 1Completed
- Sponsor
- Huabo Biopharm
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0017 in plaque psoriasis and ankylosing spondylitis (AS) (8 arms), sponsored by Huabo Biopharm. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 113 days. Started Oct 2020; status: completed.
02
Drugs
HB0017
03
Conditions
plaque psoriasisankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04505033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505033.